Reality of the ASPIRE Study
Video Categories: ASH 2014
Ajai Chari, MD, at the Mount Sinai School of Medicine in New York, deliberates on the results of the ASPIRE study as the most important thing to come out of ASH for the myeloma community. He mentions that although the study has very positive indications, the therapy isn’t really appropriate for a large portion of the myeloma population. The most practice changing piece of the study may be regarding the proven safety of carfilzomib.
January 20, 2016
Dr Wainberg and Dr Gerson discuss how biomarkers may help identify cancer stem cells.
November 24, 2014
Gary Palmer, MD, explains how research is ahead of the physician and patient and the need to educate the physician and patient on all the information about DNA and what drives the cancer.